Analysis of monitoring adverse events and problems in the treatment with sorafenib for hepatocellular carcinoma

Abstract

We retrospectively examined the adverse events related to sorafenib from March 2010 to December 2011 in 21 patients with HCC at our center. Incidence of Adverse events was 95%. HFSR, hypertension, diarrhea, malaise and hair loss were observed as adverse events. Among these, HFSR did not result in discontinuation of treatment due to the intensive skin monitoring by the team consisting of doctors, nurses and pharmacists. On the other hand, malaise was difficult to be controlled, which was the primary reason for discontinuation of treatment. We found the different pattern of adverse events within 4 weeks and after 4 weeks. Malaise is expressed after 4 weeks. Intensive monitoring of adverse events seems to be useful for controlling the treatment.